The firm looks to position its Halo lung assay for detecting cancers not found by LDCT and in average-risk populations for which LDCT screening is not currently recommended.
The approval allows the company to offer its PD-L1 IHC 22C3 pharmDx Code SK006 CDx for ovarian and other cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results